Payment overview · 2025
General Payments
$38.54
1 reported records · 1 companies
Healthcare provider profile · identity verified
Robert Lee Arnold, MPAS, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · VIDALIA, GA · NPI 1265426639
Verified facts
What the public records show
CMS Open Payments records show Robert Lee Arnold, MPAS, PA-C received $38.54 in general payments during 2025 across 1 reported records.
Lundbeck LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 561 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 85 |
| Losartan Potassium | Losartan Potassium | 374 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 75 |
| Gabapentin | Gabapentin | 341 | 74 |
| Potassium Chloride | Potassium Chloride | 303 | 61 |
| Famotidine | Famotidine | 283 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 276 | 50 |
| Furosemide | Furosemide | 251 | 53 |
| Mounjaro | Tirzepatide | 250 | 31 |
| Omeprazole | Omeprazole | 241 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 45 |
| Ozempic | Semaglutide | 209 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 52 |
| Rabeprazole Sodium | Rabeprazole Sodium | 177 | 42 |
| Spironolactone | Spironolactone | 164 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 43 |
| Trazodone Hcl | Trazodone Hcl | 151 | 34 |
| Lorazepam | Lorazepam | 150 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 27 |
| Jardiance | Empagliflozin | 141 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 132 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 30 |
| Glimepiride | Glimepiride | 119 | 28 |
| Farxiga | Dapagliflozin Propanediol | 118 | 24 |
| Memantine Hcl | Memantine Hcl | 116 | 17 |
| Clonazepam | Clonazepam | 115 | 17 |
| Tramadol Hcl | Tramadol Hcl | 115 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 25 |
| Simvastatin | Simvastatin | 110 | 29 |
| Montelukast Sodium | Montelukast Sodium | 109 | 27 |
| Lisinopril | Lisinopril | 108 | 35 |
| Meloxicam | Meloxicam | 106 | 32 |
| Allopurinol | Allopurinol | 104 | 23 |
| Azithromycin | Azithromycin | 103 | 85 |
| Buspirone Hcl | Buspirone Hcl | 103 | 17 |
| Benazepril Hcl | Benazepril Hcl | 102 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 101 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 33 |
| Eliquis | Apixaban | 96 | 22 |
| Metformin Hcl | Metformin Hcl | 95 | 27 |
| Synthroid | Levothyroxine Sodium | 93 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 23 |
| Mirtazapine | Mirtazapine | 91 | 17 |
| Linzess | Linaclotide | 89 | 16 |
| Prednisone | Prednisone | 88 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 61 |
| Sertraline Hcl | Sertraline Hcl | 82 | 13 |
| Clonidine Hcl | Clonidine Hcl | 81 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 81 | 19 |
| Ezetimibe | Ezetimibe | 80 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 44 |
| Pregabalin | Pregabalin | 75 | 11 |
| Atenolol | Atenolol | 74 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 15 |
| Carvedilol | Carvedilol | 70 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Bumetanide | Bumetanide | 65 | 24 |
| Finasteride | Finasteride | 65 | 12 |
| Bupropion Hcl | Bupropion Hcl | 63 | 14 |
| Propranolol Hcl | Propranolol Hcl | 62 | 13 |
| Doxepin Hcl | Doxepin Hcl | 60 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 24 |
| Fluconazole | Fluconazole | 55 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 11 |
| Dexamethasone | Dexamethasone | 47 | 45 |
| Cefuroxime | Cefuroxime Axetil | 46 | 27 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 14 |
| Lovastatin | Lovastatin | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Vascepa | Icosapent Ethyl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 11 |
| Valsartan | Valsartan | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Colchicine | Colchicine | 27 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 15 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 17 |
| Ramipril | Ramipril | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 17 |
| Diazepam | Diazepam | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | 12 |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Febuxostat | Febuxostat | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.54 · 1 records | Lundbeck LLC | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error